Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intercellular transfer of P-glycoprotein mediates the formation of stable multi-drug resistance in human bladder cancer BIU-87 cells.
|
30967374 |
2019 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway.
|
30349370 |
2018 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that SNPs of NR1I2 and its target genes CYP3A5 and ABCB1 are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer.
|
28676933 |
2017 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of YB-1 was correlated with the expression of p-glycoprotein and p53 in bladder cancer cases (p<0.05).
|
28714514 |
2017 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, IHC staining of human BCa tissue supported our conclusion that the expression of HIF-1α and MDR1 was higher in chemoresistant tissue vs. chemosensitive tissue.
|
26717965 |
2016 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that inhibiting ATR-Chk1 activation with WYC0209 suppresses p-glycoprotein expression and increases cisplatin activity in bladder cancer.
|
26657501 |
2016 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
P-Glycoprotein-mediated multidrug resistance is a frequent event during chemotherapy and a key obstacle for bladder cancer therapy.
|
24601223 |
2014 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report a novel mechanism of anthracycline chemoresistance in bladder cancer in which activated Twist mediates P-gp expression in addition to its antiapoptotic roles.
|
22986993 |
2012 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the molecular mechanism of doxorubicin resistance in bladder cancer with regard to p300.
|
21935574 |
2012 |
Bladder Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was aimed at examining the local distribution of GSTM1, GSTT1, MDR1, and VEGF gene polymorphisms as possible risk factors contributing to the development of bladder cancer among the population from Canary Islands, Spain.
|
21292509 |
2012 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prospective studies are warranted to define a role for MDR1 and ERCC1 analysis in individualizing multimodality treatment in locally advanced bladder cancer.
|
20689757 |
2010 |
Bladder Neoplasm
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A statistically significant inverse correlation existed between MDR1 expression and the methylation of 5'CpG sites at the promoter in patients with bladder cancer after chemotherapeutic treatment, with the degree of methylation at several CpG sites, rather than other specific sites, involved in this regulation.
|
11156211 |
2000 |
Bladder Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
|
7734314 |
1995 |
Bladder Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given that mdr1 mRNA levels are increased in a proportion of high-grade bladder tumours that are routinely subjected to chemotherapy, we discuss the possibility that mdr1 mRNA levels may be clinically significant as determinants of chemotherapeutic response and outcome in bladder cancer.
|
7908215 |
1994 |